Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 17/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.44 |
| ▸ | BRD2 | P25440 | 4/20 | 0.44 |
| ▸ | BRD3 | Q15059 | 4/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16619386 | 0.90 | BRD4 (0.43) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL1903791 | 0.88 | BRD4 (0.51) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16618802 | 0.82 | CYP3A4 (0.47) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL23728816 | 0.81 | ERN1 (0.47) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL11980664 | 0.81 | ERN1 (0.47) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL18249958 | 0.81 | ERN1 (0.45) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16619466 | 0.80 | BRD4 (0.48) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL18249961 | 0.80 | ERN1 (0.46) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL18249964 | 0.80 | ERN1 (0.46) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16619017 | 0.77 | AKR1C3 (0.47) | CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015049629-A1 | IMIDAZOQUINOLINE COMPOUNDS AS BROMODOMAIN INHIBITORS | Piramal Enterprises Limited (IN) | 2015-04-09 | — | — | WO | disclosed |